Skip to main content
Top
Published in: Rheumatology International 6/2009

01-04-2009 | Original Article

Patients with active rheumatoid arthritis but only few tender and swollen joints: a subgroup with impaired short term outcome

Authors: C. Fiehn, S. Kessler, W. Drexler, H. M. Lorenz

Published in: Rheumatology International | Issue 6/2009

Login to get access

Abstract

The disease activity score of 28 joints (DAS28) is now commonly used for the guidance of treatment decisions in rheumatoid arthritis (RA). The goal of this work was to determine whether patients with DAS28 > 3.2 but less than 2 swollen and 2 tender joints respond differently to treatment than patients with a higher number of active joints. One hundred and ninety two patients with active RA treated in a rheumatology hospital as in-patients were studied prospectively. At admission (T1), release (T2) and 3 months after release (T3) disease activity (DAS28-CRP at T1 + 2, RADAI at T1 + 3), pain (numeric scale at T1 − 3) and function (FFbH at T1 + 3) were measured. A total of 148 patients had two or more (group 1) and 44 less than 2 swollen and tender joints at admission (group 2) but both groups had similar over all DAS28-scores. The groups significantly differed in their outcome after 3 months: group 1 had a significant better reduction of disease activity, pain and functional deficit (p < 0.001 for the fulfilment of defined response criteria and p < 0.05 for comparison of the mean values for pain and function) in comparison to group 2. Although the numbers were small sub-analysis suggested that the differences might be due to a better response to newly administered DMARD and TNF-alpha-inhibitor therapy in group 1. Active RA patients with less than 2 swollen and 2 tender joints represent a subgroup with lower response to treatment with DMARD or TNF-alpha-inhibitors. This has to be taken into account in the management of these patients.
Literature
1.
go back to reference Soubrier M, Zerkak D, Gossec L, Ayral X, Roux C, Dougados M (2006) Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol 33:1243–1246PubMed Soubrier M, Zerkak D, Gossec L, Ayral X, Roux C, Dougados M (2006) Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol 33:1243–1246PubMed
2.
go back to reference Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Wested ML, Gerards AH, van Groendendael JM, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA (2006) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381–3390CrossRef Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Wested ML, Gerards AH, van Groendendael JM, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA (2006) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381–3390CrossRef
3.
go back to reference Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269PubMedCrossRef Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269PubMedCrossRef
4.
go back to reference Landewe R, van der Heijde D, van der Linden S, Boers M (2006) Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 65:637–641PubMedCrossRef Landewe R, van der Heijde D, van der Linden S, Boers M (2006) Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 65:637–641PubMedCrossRef
5.
go back to reference Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, Kirkpatrick J (1995) Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 38:38–43PubMedCrossRef Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, Kirkpatrick J (1995) Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 38:38–43PubMedCrossRef
6.
go back to reference van Gestel AM, Prevoo ML, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:34–40PubMedCrossRef van Gestel AM, Prevoo ML, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:34–40PubMedCrossRef
7.
go back to reference Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J (2006) Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 54:3399–3407PubMedCrossRef Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J (2006) Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 54:3399–3407PubMedCrossRef
8.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
9.
go back to reference Verband Rheumatologischer Akutkliniken (VRA) (2007) Outcome Benchmarking in der Rheumatologischen Akutversorgung. Schüling Verlag, Münster Verband Rheumatologischer Akutkliniken (VRA) (2007) Outcome Benchmarking in der Rheumatologischen Akutversorgung. Schüling Verlag, Münster
10.
go back to reference Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of disease activity score (DAS) 28-erythrocyte sedimentation rate and DAS28-c-reactive protein threshold values. Ann Rheum Dis 66:407–409PubMedCrossRef Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of disease activity score (DAS) 28-erythrocyte sedimentation rate and DAS28-c-reactive protein threshold values. Ann Rheum Dis 66:407–409PubMedCrossRef
11.
go back to reference Fransen J, Langenegger T, Michel BA, Stucki G (2000) Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford) 39:321–327CrossRef Fransen J, Langenegger T, Michel BA, Stucki G (2000) Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford) 39:321–327CrossRef
12.
go back to reference Raspe H, Hagedorn U, Kohlmann T, Mattussek S (1999) Der Funktionsfragebogen Hannover (FFbH): Ein Instrument zur Funktionsdiagnostikbei polyartikulären Gelenkerkrankungen. In: Siegrist J (ed) Wohnortnahe Betreuung Rheumakranker. Stuttgart, Schattauer, pp 164–182 Raspe H, Hagedorn U, Kohlmann T, Mattussek S (1999) Der Funktionsfragebogen Hannover (FFbH): Ein Instrument zur Funktionsdiagnostikbei polyartikulären Gelenkerkrankungen. In: Siegrist J (ed) Wohnortnahe Betreuung Rheumakranker. Stuttgart, Schattauer, pp 164–182
13.
go back to reference Fransen J, Hauselmann H, Michel BA, Caravatti M, Stucki G (2001) Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity. Arthritis Rheum 44:53–60PubMedCrossRef Fransen J, Hauselmann H, Michel BA, Caravatti M, Stucki G (2001) Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity. Arthritis Rheum 44:53–60PubMedCrossRef
14.
go back to reference Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 343:1594–1602 Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 343:1594–1602
15.
go back to reference Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden JR, Malaise M, Mola EM, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675–681PubMedCrossRef Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden JR, Malaise M, Mola EM, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675–681PubMedCrossRef
16.
go back to reference Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B (2004) The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology (Oxford) 43:1504–1507CrossRef Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B (2004) The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology (Oxford) 43:1504–1507CrossRef
17.
go back to reference Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B (2007) Disease activity score-28 values differ considerably depending on patient’s pain perception and sex. J Rheumatol 34:2382–2387PubMed Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B (2007) Disease activity score-28 values differ considerably depending on patient’s pain perception and sex. J Rheumatol 34:2382–2387PubMed
18.
go back to reference Hurst NP, Ruta DA, Kind P (1998) Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Br J Rheumatol 37:862–869PubMedCrossRef Hurst NP, Ruta DA, Kind P (1998) Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Br J Rheumatol 37:862–869PubMedCrossRef
Metadata
Title
Patients with active rheumatoid arthritis but only few tender and swollen joints: a subgroup with impaired short term outcome
Authors
C. Fiehn
S. Kessler
W. Drexler
H. M. Lorenz
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 6/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-008-0753-y

Other articles of this Issue 6/2009

Rheumatology International 6/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.